Full Breakdown
Varda and United Therapeutics Launch First Pharma Partnership for Microgravity Drug Development
5/14/2026, 12:38:45 AM
Core Event: First Commercial Pharma Collaboration in Low-Earth Orbit
On 13 May 2026 Varda Space Industries announced a partnership with United Therapeutics to run drug-formulation experiments in low-Earth orbit using Varda’s autonomous W-series capsules, targeting rare pulmonary disease treatments.
Background & Context: From Shuttle Experiments to Dedicated Capsules
Microgravity research began on the Space Shuttle and continued on the ISS, where a 2019 experiment produced a Keytruda crystal. ISS studies face scheduling and return delays. Varda’s capsules, launched (W-1), spend weeks in orbit and return payloads in weeks, removing astronaut involvement.
Data & Statistics: Flights, Funding, and Supporting Contracts
Varda has flown six W-series missions (W-1–W-6) by March 2026. A July 2025 Series C round raised $187 million, bringing capital to $329 million to build a pharmaceutical lab and launches. United Therapeutics’ rare pulmonary disease portfolio commands per-gram value, aligning with Varda’s model. Varda holds a $48 million Air Force re-entry contract.
Why It Matters: Potential Benefits and Economic Implications
Microgravity can produce drug polymorphs with altered solubility, stability or bioavailability, extending patents or enabling delivery routes. In rare pulmonary diseases, where options are limited and prices high, modest improvements could be valuable. An orbital manufacturing process would broaden the orbital economy beyond government contracts.
Official Statements & Responses
Varda called microgravity a manufacturing environment and said the partnership bridges science to patient benefit. United Therapeutics said the collaboration lets it explore space-derived improvements for rare pulmonary disease therapies and praised Varda’s routineized access versus ISS logistics.
Criticism & Opposition
Returning gram-scale active ingredient is unproven at volumes and regulatory pathways for space-grown crystals are identical to terrestrial products, creating cost-effectiveness uncertainty. The deal alone does not prove a viable orbital drug-manufacturing industry.
Conflicting Reports & Gaps
The agreement does not disclose a timeline for the drug studies or the financial terms, and it lacks details on how the resulting crystal forms will satisfy regulatory requirements.
Verbatim Quotes
- “This is the first time that a large, publicly traded company is using capital from their own balance sheet, not just from NASA, to build and produce a product in microgravity,” — Delian Asparouhov, President and Co-Founder, Varda Space Industries
- “Microgravity gives us a fundamentally different environment to manufacture pharmaceuticals that are otherwise impossible on Earth,” — Will Bruey, Chief Executive, Varda Space Industries
- “The collaboration with Varda will allow us to explore how space-based manufacturing could contribute to significant improvements for rare pulmonary disease treatments,” — Martine Rothblatt, Chair and Chief Executive, United Therapeutics
- “People can do things like this with the space station, and I have thought about it many a time, but it is such a logistical hassle to get up to the space station,” — Martine Rothblatt, Chair and Chief Executive, United Therapeutics
What’s Next
The partnership’s first formulation experiments will fly on upcoming W-series missions later in 2026. Results will show whether the microgravity-derived crystals meet performance and regulatory criteria, guiding expansion to other therapies or commercial space-station production.
